SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001654954-24-006228
Filing Date
2024-05-14
Accepted
2024-05-14 16:01:36
Documents
52
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tenx_10q.htm   iXBRL 10-Q 554001
2 CERTIFICATION tenx_ex311.htm EX-31.1 10963
3 CERTIFICATION tenx_ex312.htm EX-31.2 10843
4 CERTIFICATION tenx_ex321.htm EX-32.1 4660
5 CERTIFICATION tenx_ex322.htm EX-32.2 4754
  Complete submission text file 0001654954-24-006228.txt   2816945

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tenx-20240331.xsd EX-101.SCH 36586
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20240331_lab.xml EX-101.LAB 187209
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20240331_cal.xml EX-101.CAL 30076
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20240331_pre.xml EX-101.PRE 165793
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20240331_def.xml EX-101.DEF 98891
56 EXTRACTED XBRL INSTANCE DOCUMENT tenx_10q_htm.xml XML 316610
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

IRS No.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34600 | Film No.: 24944095
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)